ME00122B - Sistemi koji obezbjeđuju podržano oslobađanje lijeka - Google Patents
Sistemi koji obezbjeđuju podržano oslobađanje lijekaInfo
- Publication number
- ME00122B ME00122B MEP-2008-200A MEP2008200A ME00122B ME 00122 B ME00122 B ME 00122B ME P2008200 A MEP2008200 A ME P2008200A ME 00122 B ME00122 B ME 00122B
- Authority
- ME
- Montenegro
- Prior art keywords
- coating layer
- inner core
- agent
- effective agent
- impermeable
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract 11
- 238000013268 sustained release Methods 0.000 title claims abstract 7
- 239000012730 sustained-release form Substances 0.000 title claims abstract 7
- 239000011247 coating layer Substances 0.000 claims abstract 57
- 239000003795 chemical substances by application Substances 0.000 claims abstract 31
- 238000000034 method Methods 0.000 claims abstract 18
- 230000009885 systemic effect Effects 0.000 claims abstract 5
- 230000000144 pharmacologic effect Effects 0.000 claims abstract 4
- 230000001766 physiological effect Effects 0.000 claims abstract 4
- 229940079593 drug Drugs 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 238000013269 sustained drug release Methods 0.000 claims 8
- 239000010410 layer Substances 0.000 claims 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims 2
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 2
- 229960001347 fluocinolone acetonide Drugs 0.000 claims 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical group O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 2
- 229960002963 ganciclovir Drugs 0.000 claims 2
- 229960000715 nimodipine Drugs 0.000 claims 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 2
- 229920001296 polysiloxane Polymers 0.000 claims 2
- 238000004073 vulcanization Methods 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Obezbeđeni su postupak i sistem za tretiranje organizma sisara radi dobijanja željenog lokalnog ili sistemskog fiziološkog ili farmakološkog efekta. Postupak obuhvata primenu sistema za isporuku leka sa podržanim oslobađanjem leka u organizmu sisara koji treba takav tretman na područje gde se želi oslobađanje efektivnog agensa gde postupak obezbeđuje da efektivni agens prolazi kroz sistem na kontrolisan način. Sistem obuhvata unutrašnje jezgro ili rezervoar koji obuhvata efektivni agens; prvi prevlačeći sloj koji je propustljiv za prolazak efektivnog agensa; drugi prevlačeći sloj koji je uglavnom nepropustljiv za prolazak efektivnog agensa; i treći prevlačeći sloj, koji je propustljiv za prolazak efektivnog agensa. Prvi prevlačeći sloj prekriva bar deo unutrašnjeg jezgra. Drugi prevlačeći sloj prekriva bar deo prvog prevlačećeg sloja i unutrašnjeg jezgra; gde bar mali deo prvog prevlačećeg sloja ili unutrašnjeg jezgra nije prekriven sa drugim prevlačećem slojem. Drugi prevlačeći sloj obuhvata nepropustljiv film i bar jedan nepropustljiv disk. Treći prevlačeći sloj uglavnom potpuno prekriva drugi prevlačeći sloj i neprevlačeni deo prvog prevlačećeg sloja •ili unutrašnjeg jezgra. Obezbeđeni su postupak i sistem za tretiranje organizma sisara radi dobijanja željenog lokalnog ili sistemskog fiziološkog ili farmakološkog efekta. Postupak obuhvata primenu sistema za isporuku leka sa podržanim oslobađanjem leka u organizmu sisara koji treba takav tretman na područje gde se želi oslobađanje efektivnog agensa gde postupak obezbeđuje da efektivni agens prolazi kroz sistem na kontrolisan način. Sistem obuhvata unutrašnje jezgro ili rezervoar koji obuhvata efektivni agens; prvi prevlačeći sloj koji je propustljiv za prolazak efektivnog agensa; drugi prevlačeći sloj koji je uglavnom nepropustljiv za prolazak efektivnog agensa; i treći prevlačeći sloj, koji je propustljiv za prolazak efektivnog agensa. Prvi prevlačeći sloj prekriva bar deo unutrašnjeg jezgra. Drugi prevlačeći sloj prekriva bar deo prvog prevlačećeg sloja i unutrašnjeg jezgra; gde bar mali deo prvog prevlačećeg sloja ili unutrašnjeg jezgra nije prekriven sa drugim prevlačećem slojem. Drugi prevlačeći sloj obuhvata nepropustljiv film i bar jedan nepropustljiv disk. Treći prevlačeći sloj uglavnom potpuno prekriva drugi prevlačeći sloj i neprevlačeni deo prvog prevlačećeg sloja •ili unutrašnjeg jezgra.
Claims (21)
1. Postupak za obezbeđivanje kontrolisane i podržane primene agensa koji je efektivan u dobijanju željenog lokalnog ili sistemskog fiziološkog ili fannakološkog efekta, naznačen time, što obuhvata: hiruršku implataciju sistema za isporuku leka sa podržanim oslobađanjem na željenu lokaciju, pomenuti sistem za isporuku Jeka obuhvata:(l) unutrašnje jezgro ili rezervoar koji obuhvata efektivnu količinu agensakoja je efektivna za dobijanje željenog lokalnog ili sistemskog fiziološkog ili farmakološkog efekta,(2) prvi prevlčeći sloj koji je propustljiv za prolazak pomenutog agensa, gde pomenuti prvi prevlačeći sloj prekriva bar deo pomenutog unutrašnjeg jezgra, koji obezbeđuje kontrolu ipodržano oslobađanje agensa,(3) drugi prevlačeći sloj, pomenuti drugi prevlačeći sloj je uglavnom nepropustljiv na prolazak pomenutog agensa, i pomenuti drugi prevlačeći sloj koji prekriva bar 50% unutrašnjeg jezgra i/ili prvog prevlačećeg sloja, gde bar mali deo unutrašnjeg jezgra ili prvog prevlačećeg sloja nije prekriven sa pomenutim drugim prevlačećim slojem i pomenuti drugi prevlačeći sloj obuhvata nepropustljivi film i bar jedan nepropustljivi disk koji je od različitog matreijala ili koji ima uglavnom veću tvrdoću, debljinu, rastegljivost ili odgovor na toplotno vulkanizovanje nego što je nepropustljivi film, i(4) treći prevlačeći sloj koji je propustljiv za prolazak pomenutog agensa, gde pomenuti treći prevlačeći sloj uglavnom potpuno prekriva pomenuti drugi prevlačeći sloj i nepokriveni deo prvog prevlačećeg sloja ili unutrašnjeg jezgra, tako da pomenuti agens može da prođe korz pomenuti treći prevlačeći sloj na kontrolisani način.
2.postupak prema zahtevu 1, naznačen time, što pomenuti prvi i trći prevlačeći slojevi obuhvataju polivinil alkohol.
3.Postupak prema zahtevu l, naznačen time, što pomenuti treći prevlačeći sloj je silikon.
4.Postupak prema zahtevu 2, naznačen time, što pomenuti drugi prevlačeći sloj obuhvata etilen vinil acetat.
5.Postupak prema zahtevu 4, naznačen time, što pomenuti efektivni agens je ganciklovir ili 5-fluororacuil.
6.Postupak prema zahtevu 4, naznačen time, što pomenuti efektivni agens je nisko rastvoran steroid.
7.Postupak prema zahtevu 6, naznačen time, što pomenuti nisko rastvoran steroid je fluocinolon acetonid.
8.Postupak prema zahtevu 4, naznačen time, što pomenuti efektivni agens je neuroprotektant. .. 15
9.Postupak prema zahtevu 8, naznačen time, što pomenuti neuroprotektant je nimodipin. l O.
10. Sistem za isporuku leka sa podržanim oslobađanjem leka, naznačen time, što obuhvata: (A) unutrašnje jezgro ili rezervoar koji obuhvata efektivnu količinu agensa radi dobijanja željenog lokalnog ili sistemskog fiziološkog ili farmakološkog efekta, (B) prvi prevlčeći sloj koji je propustljiv za prolazak pomenutog agensa, gde pomenuti prvi prevlačeći sloj prekriva bar deo pomenutog unutrašnjeg jezgra, koji obezbeđuje kontrolu i podržano oslobađanje agensa, (C) drugi prevlačeći sloj, pomenuti drugi prevlačeći sloj je uglavnom nepropustljiv na prolazak pomenutog agensa, i pomenuti drugi prevlačeći sloj koji prekriva bar 50% unutrašnjeg jezgra i/ili prvog prevlačećeg sloja, gde bar mali deo unutrašnjeg jezgra ili prvog prevlačećeg sloja nije prekriven sa pomenutim drugim prevlačećim slojem i pomenuti drugi prevlačeći sloj obuhvata nepropustljivi film i bar jedan nepropustljivi disk koji je od različitog matreijala ili koji ima uglavnom veću tvrdoću, debljinu, rastegljivost ili odgovor na toplotno vulkanizovanje nego što ima nepropustljiv film, i (D) treći prevlačeći sloj, pomenuti prevlačeći sloj je propustljiv za prolazak pomenutog efektivnog agensa, gde pomenuti treći prevlačeći sloj uglavnom potpuno prekriva pomenuti drugi prevlačeći sloj i nepokriveni deo prvog prevlačećeg sloja ili unutrašnjeg jezgra.
11.Sistem za isporuku leka sa podržanim oslobađanjem leka prema zahtevu l O, naznačen time, što pomenuti treći prevlačeći sloj obuhvata polivinil alkohol
12.Sistem za isporuku leka sa podržanim oslobađanjem leka prema zahtevu ll , naznačen time, što pomenuti drugi prevlačeći sloj obuhvata etilen vinil acetat.
13.Sistem za isporuku teka sa podržanim oslobađanjem leka prema zahtevu 12, naznačen time, što pomenuti prvi prevlačeći sloj obuhvata polivinil akohol.
14. Sistem za isporuku leka sa podržanim oslobađanjem leka prema zahtevu 13, naznačen time, što pomenuti efektivni agens je ganciklover ili fluocinolon acetonid.
15.Sistem za isporuku teka sa podržanim oslobađanjem teka prema zahtevu 1O, naznačen time, što pomenuti efektivni agens je nimodipin.
16.Sistem za isporuku leka sa podržanim oslobađanjem leka prema zahtevu l O, naznačen time, što treći prevlačeći sloj obuhvata silikon.
17.Postupak prema zahtevu l, naznačen time, što pomenuti nepropustljivi film je načinjen od matreijala koji se razlikuje od onog za pomenuti nepropustljivi disk.
18.Postupak prema zahtevu l, naznačen time, što pomenuti drugi prevlačeći sloj pokriva celokupno unutrašnje jezgro iprvi prevlačeći sloj sa izuzetkom difuzionog otvora. .. 16
19.Postupak prema zahtevu l, naznačen time, što pomenuti nepropustljivi disk je tvrdi od pomenutog nepropustljivog fllma.
20.Sistem za isporuku leka sa podržanim oslobađanjem leka prema zahtevu 10, naznačen time, što pomenuti efektivni agens je steroid.
21.Sistem za isporuku leka sa podržanim oslobađanjem leka prema zahtevu 10, naznačen time, što pomenuti efektivni agens je neuroprotektant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/919,221 US5902598A (en) | 1997-08-28 | 1997-08-28 | Sustained release drug delivery devices |
| PCT/US1998/017342 WO1999011244A1 (en) | 1997-08-28 | 1998-08-28 | Sustained release drug delivery devices |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME00122B true ME00122B (me) | 2010-10-10 |
Family
ID=25441727
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-200A ME00122B (me) | 1997-08-28 | 1998-08-28 | Sistemi koji obezbjeđuju podržano oslobađanje lijeka |
| MEP-200/08A MEP20008A (en) | 1997-08-28 | 1998-08-28 | Sustained release drug delivery devices |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-200/08A MEP20008A (en) | 1997-08-28 | 1998-08-28 | Sustained release drug delivery devices |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5902598A (me) |
| EP (1) | EP1009388B1 (me) |
| JP (2) | JP4530531B2 (me) |
| KR (1) | KR20010023358A (me) |
| CN (2) | CN100453074C (me) |
| AR (1) | AR017026A1 (me) |
| AT (1) | ATE548029T1 (me) |
| AU (1) | AU741846B2 (me) |
| BR (1) | BR9811381A (me) |
| CA (1) | CA2301685C (me) |
| CZ (1) | CZ302339B6 (me) |
| EA (1) | EA002162B1 (me) |
| HU (1) | HUP0002797A3 (me) |
| IL (1) | IL134568A (me) |
| ME (2) | ME00122B (me) |
| NO (1) | NO327752B1 (me) |
| NZ (2) | NZ502836A (me) |
| PL (1) | PL344039A1 (me) |
| RS (1) | RS52096B (me) |
| SG (1) | SG121718A1 (me) |
| TR (1) | TR200001029T2 (me) |
| TW (1) | TWI222884B (me) |
| UA (1) | UA71898C2 (me) |
| WO (1) | WO1999011244A1 (me) |
Families Citing this family (277)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
| US6117643A (en) * | 1997-11-25 | 2000-09-12 | Ut Battelle, Llc | Bioluminescent bioreporter integrated circuit |
| JP2002534139A (ja) * | 1999-01-05 | 2002-10-15 | マサチューセッツ・アイ・アンド・イア・インファーマリー | 網膜と脈絡膜への経強膜徐放性薬剤標的送達 |
| US20040121014A1 (en) * | 1999-03-22 | 2004-06-24 | Control Delivery Systems, Inc. | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| ATE290837T1 (de) | 1999-10-21 | 2005-04-15 | Alcon Inc | Medikamentenversorgung der sub-tenon |
| US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| BR0014929B1 (pt) | 1999-10-21 | 2009-01-13 | dispositivo para distribuiÇço de medicamento oftÁlmico. | |
| US7943162B2 (en) * | 1999-10-21 | 2011-05-17 | Alcon, Inc. | Drug delivery device |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| US20040208910A1 (en) * | 2000-04-26 | 2004-10-21 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of adrenergic agents |
| US20040115268A1 (en) * | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
| US20040175410A1 (en) * | 2000-04-26 | 2004-09-09 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
| US7452964B2 (en) * | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
| US20050074747A1 (en) * | 2000-09-08 | 2005-04-07 | Wadih Arap | Biopanning and rapid analysis of selective interactive ligands (brasil) |
| US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
| US7420030B2 (en) | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
| AU2002232399A1 (en) * | 2000-11-03 | 2002-05-15 | Control Delivery Systems | Improved device and method for treating conditions of a joint |
| ATE306951T1 (de) * | 2000-11-29 | 2005-11-15 | Allergan Inc | Verhinderung von transplantatabstossung im auge |
| EP1345588A2 (en) | 2000-12-29 | 2003-09-24 | Bausch & Lomb Incorporated | Sustained release drug delivery devices |
| EP1847255A3 (en) * | 2001-01-03 | 2009-03-04 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with coated drug cores |
| CA2432225C (en) * | 2001-01-03 | 2008-01-15 | Michael J. Brubaker | Sustained release drug delivery devices with prefabricated permeable plugs |
| ES2294043T3 (es) * | 2001-01-03 | 2008-04-01 | BAUSCH & LOMB INCORPORATED | Dispositivos de liberacion prolongada de medicamentos que comprenden nucleos recubiertos de medicamentos. |
| US6756058B2 (en) | 2001-01-03 | 2004-06-29 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with multiple agents |
| EP1365738A2 (en) * | 2001-01-26 | 2003-12-03 | Bausch & Lomb Incorporated | Improved process for the production of sustained release drug delivery devices |
| US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US20050215727A1 (en) * | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
| EP1390084B1 (en) * | 2001-05-01 | 2011-03-23 | A.V. Topchiev Institute of Petrochemical Synthesis | Two-phase, water-absorbent bioadhesive composition |
| US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
| US8541021B2 (en) * | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
| US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
| US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
| RU2276998C2 (ru) | 2001-05-01 | 2006-05-27 | Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук | Гидрогелевые композиции |
| JP2004536631A (ja) | 2001-05-03 | 2004-12-09 | マサチューセッツ・アイ・アンド・イア・インファーマリー | 移植可能な薬物送達デバイスおよびその使用 |
| CA2450771C (en) * | 2001-06-12 | 2010-09-07 | Johns Hopkins University School Of Medicine | Reservoir device for intraocular drug delivery |
| US20040176290A1 (en) * | 2001-07-18 | 2004-09-09 | Renata Pasqualini | Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration |
| BR0210494A (pt) | 2001-07-23 | 2004-06-22 | Alcon Inc | Dispositivo de administração de droga oftálmica |
| BR0210287A (pt) * | 2001-07-23 | 2005-12-13 | Alcon Inc | Dispositivo de administração de droga oftalmológica |
| US7749528B2 (en) * | 2001-08-29 | 2010-07-06 | Ricardo Azevedo Pontes De Carvalho | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
| EP1420716B1 (en) | 2001-08-29 | 2012-08-15 | Ricardo A. P. De Carvalho | An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues |
| US20040048243A1 (en) * | 2001-09-07 | 2004-03-11 | Wadih Arap | Methods and compositions for in vitro targeting |
| US7671010B2 (en) * | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| US8507445B2 (en) * | 2001-09-07 | 2013-08-13 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| US20030158598A1 (en) * | 2001-09-17 | 2003-08-21 | Control Delivery Systems, Inc. | System for sustained-release delivery of anti-inflammatory agents from a coated medical device |
| ATE345680T1 (de) * | 2002-01-31 | 2006-12-15 | Disease Control Textiles Sa | Laminierte vorrichtung für insektizide |
| US20030229333A1 (en) * | 2002-02-22 | 2003-12-11 | Control Delivery Systems, Inc. | Methods for treating otic disorders |
| EP2522319A3 (en) * | 2002-03-11 | 2013-09-25 | Novartis AG | Implantable drug delivery system |
| WO2003087367A2 (en) * | 2002-04-18 | 2003-10-23 | Lynkeus Biotech Gmbh | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| WO2003092514A1 (en) * | 2002-05-02 | 2003-11-13 | Control Delivery Systems, Inc. | Device and method for treating conditions of a joint |
| AU2003217531A1 (en) * | 2002-05-02 | 2003-11-17 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| AU2003234439A1 (en) * | 2002-05-07 | 2003-11-11 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| EP1507826A4 (en) | 2002-05-17 | 2007-11-07 | Othera Pharmaceuticals Inc | IMPROVING THE EVOLUTION OF CATARACTS AND OTHER OPHTHALMIC DISEASES |
| ATE382330T1 (de) * | 2002-07-15 | 2008-01-15 | Alcon Inc | Nichtpolymere lipophile pharmazeutische implantat-zusammensetzungen für die intraokulare anwendung |
| US20070184089A1 (en) * | 2002-07-15 | 2007-08-09 | Alcon, Inc. | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| WO2004036182A2 (en) * | 2002-10-17 | 2004-04-29 | Control Delivery Systems, Inc. | Methods for monitoring treatment of disease |
| WO2004043435A2 (en) * | 2002-11-13 | 2004-05-27 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
| CA2453013C (en) * | 2002-12-13 | 2011-02-15 | Gary W. Cleary | Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
| EP1572216A1 (en) * | 2002-12-20 | 2005-09-14 | Control Delivery Systems, Inc. | Steroid compositions for intraocular use |
| US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| EP2251434B1 (en) | 2003-01-16 | 2014-07-30 | The Trustees of The University of Pennsylvania | Compositions and methods for siRNA inhibition of ICAM-1 |
| ATE440595T1 (de) * | 2003-01-24 | 2009-09-15 | Psivida Inc | Vorrichtung mit verlängerter freisetzung und verfahren zur okularen verabreichung von adrenergen wirkstoffen |
| CN100594899C (zh) * | 2003-01-24 | 2010-03-24 | 控制递送系统有限公司 | 经眼部递送碳酸酐酶抑制剂的持续释放系统和方法 |
| KR20050108345A (ko) * | 2003-01-24 | 2005-11-16 | 컨트롤 딜리버리 시스템즈 인코포레이티드 | 탄산 탈수효소 저해제의 안구 전달을 위한 서방 장치와방법 |
| US20050019400A1 (en) * | 2003-01-27 | 2005-01-27 | Deveney Thomas William | Controlled-release drug delivery system |
| US20060167435A1 (en) * | 2003-02-18 | 2006-07-27 | Adamis Anthony P | Transscleral drug delivery device and related methods |
| US9445901B2 (en) * | 2003-03-12 | 2016-09-20 | Deger C. Tunc | Prosthesis with sustained release analgesic |
| US7037521B2 (en) * | 2003-03-28 | 2006-05-02 | Bausch & Lomb Incorporated | Using a laser for cutting a hole in a capsule for controlled drug delivery |
| US20050261668A1 (en) * | 2003-03-28 | 2005-11-24 | Bausch & Lomb Incorporated | Drug delivery device |
| US7589107B2 (en) | 2003-05-19 | 2009-09-15 | Othera Holding, Inc. | Amelioration of vitrectomy-induced cataracts |
| US7825134B2 (en) * | 2003-05-19 | 2010-11-02 | Othera Holding, Inc. | Amelioration of cataracts, macular degeneration and other ophthalmic diseases |
| US7553298B2 (en) * | 2003-12-19 | 2009-06-30 | Ethicon Endo-Surgery, Inc. | Implantable medical device with cover and method |
| US8715243B2 (en) * | 2003-06-16 | 2014-05-06 | Ethicon Endo-Surgery, Inc. | Injection port applier with downward force actuation |
| US7561916B2 (en) | 2005-06-24 | 2009-07-14 | Ethicon Endo-Surgery, Inc. | Implantable medical device with indicator |
| US7862546B2 (en) * | 2003-06-16 | 2011-01-04 | Ethicon Endo-Surgery, Inc. | Subcutaneous self attaching injection port with integral moveable retention members |
| US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
| US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
| US7875272B2 (en) * | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
| US8491883B2 (en) * | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
| WO2005001080A2 (en) | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system |
| US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
| US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
| US20050054586A1 (en) * | 2003-06-30 | 2005-03-10 | Bartels Stephen P. | Treatment of ophthalmic disorders |
| US20040265356A1 (en) * | 2003-06-30 | 2004-12-30 | Bausch & Lomb Incorporated | Drug delivery device |
| WO2005007020A2 (en) * | 2003-07-03 | 2005-01-27 | Corium International, Inc. | Wound dressing, ingredient delivery device and iv hold-down, and method relating to same |
| ZA200508654B (en) * | 2003-07-10 | 2007-01-31 | Alcon Inc | Ophthalmic drug delivery device |
| WO2005027906A1 (en) * | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| NZ575950A (en) * | 2003-11-13 | 2010-06-25 | Psivida Inc | Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin |
| CA2546042A1 (en) * | 2003-11-20 | 2005-06-09 | Othera Pharmaceuticals, Inc. | Amelioration of macular degeneration and other ophthalmic diseases |
| US8162897B2 (en) * | 2003-12-19 | 2012-04-24 | Ethicon Endo-Surgery, Inc. | Audible and tactile feedback |
| US20050148948A1 (en) * | 2003-12-19 | 2005-07-07 | Caputa Steven G. | Sutureless ophthalmic drug delivery system and method |
| DE10360185A1 (de) * | 2003-12-20 | 2005-08-04 | Max Wyssmann | Vorrichtung zur gezielten, steuerbaren Abgabe oder zum Ansaugen einer Flüssigkeit oder einer viskosen Masse |
| US20050158365A1 (en) | 2003-12-22 | 2005-07-21 | David Watson | Drug delivery device with mechanical locking mechanism |
| US7211272B2 (en) * | 2003-12-22 | 2007-05-01 | Bausch & Lomb Incorporated | Drug delivery device |
| US20050137538A1 (en) | 2003-12-22 | 2005-06-23 | Bausch & Lomb Incorporated | Drug delivery device |
| US20050136095A1 (en) * | 2003-12-22 | 2005-06-23 | Brian Levy | Drug delivery device with suture ring |
| US20070053963A1 (en) * | 2004-01-13 | 2007-03-08 | Hotchkiss Robert N | Drug delivery to a joint |
| AU2005209242A1 (en) * | 2004-01-26 | 2005-08-11 | Psivida Inc. | Controlled and sustained delivery of nucleic acid-based therapeutic agents |
| EP1713450B1 (en) | 2004-01-30 | 2021-10-06 | Corium, Inc. | Rapidly dissolving film for delivery of an active agent |
| US20060018949A1 (en) * | 2004-04-07 | 2006-01-26 | Bausch & Lomb Incorporated | Injectable biodegradable drug delivery system |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20070254950A1 (en) * | 2004-05-25 | 2007-11-01 | Othera Pharmaceuticals, Inc. | Oculoselective Drugs and Prodrugs |
| EP1765336A4 (en) | 2004-06-25 | 2010-03-10 | Univ Johns Hopkins | ANGIOGENESIS INHIBITORS |
| US20060110428A1 (en) | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
| WO2006014434A2 (en) | 2004-07-02 | 2006-02-09 | Eliot Lazar | Treatment medium delivery device and methods for delivery |
| WO2006017807A2 (en) * | 2004-08-05 | 2006-02-16 | Corium International, Inc. | Adhesive composition |
| US20060068012A1 (en) * | 2004-09-29 | 2006-03-30 | Bausch & Lomb Incorporated | Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control |
| US20060067978A1 (en) * | 2004-09-29 | 2006-03-30 | Bausch & Lomb Incorporated | Process for preparing poly(vinyl alcohol) drug delivery devices |
| US20060067979A1 (en) * | 2004-09-30 | 2006-03-30 | Bausch & Lomb Incorporated | Ophthalmic drug release device for multiple drug release |
| WO2006039459A1 (en) * | 2004-09-30 | 2006-04-13 | Bausch & Lomb Incorporated | Capsule for encasing tablets for surgical insertion into the human body |
| US20060078592A1 (en) * | 2004-10-12 | 2006-04-13 | Bausch & Lomb Incorporated | Drug delivery systems |
| US20070276481A1 (en) * | 2004-12-08 | 2007-11-29 | Renner Steven B | Drug delivery device |
| US20060134162A1 (en) * | 2004-12-16 | 2006-06-22 | Larson Christopher W | Methods for fabricating a drug delivery device |
| WO2006083394A2 (en) * | 2004-12-21 | 2006-08-10 | Ethicon, Inc. | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
| US20060171930A1 (en) * | 2004-12-21 | 2006-08-03 | Agnieszka Seyda | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
| US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
| US20060134175A1 (en) * | 2004-12-22 | 2006-06-22 | Stephen Bartels | Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use |
| US20060134174A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
| WO2006068898A1 (en) * | 2004-12-22 | 2006-06-29 | Bausch & Lomb Incorporated | Reusable drug delivery device |
| US20060134176A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
| CA2589041C (en) | 2004-12-23 | 2019-08-20 | Ethicon, Incorporated | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
| JP5425399B2 (ja) | 2004-12-23 | 2014-02-26 | エシコン・インコーポレイテッド | 産褥由来細胞を用いたパーキンソン病および関連の障害の治療 |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| KR20070104931A (ko) * | 2005-02-09 | 2007-10-29 | 마커사이트, 인코포레이티드 | 안구 치료용 제제 |
| AU2006227116A1 (en) * | 2005-03-21 | 2006-09-28 | Santen Pharmaceutical Co., Ltd. | Drug delivery systems for treatment of diseases or conditions |
| CA2601864A1 (en) * | 2005-04-08 | 2006-10-19 | Surmodics, Inc. | Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease |
| US20080312283A1 (en) * | 2005-05-26 | 2008-12-18 | Othera Pharmaceuticals, Inc. | Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts |
| US7651483B2 (en) * | 2005-06-24 | 2010-01-26 | Ethicon Endo-Surgery, Inc. | Injection port |
| US7918844B2 (en) | 2005-06-24 | 2011-04-05 | Ethicon Endo-Surgery, Inc. | Applier for implantable medical device |
| US20060292202A1 (en) * | 2005-06-27 | 2006-12-28 | Bausch & Lomb Incorporated | Drug delivery device |
| US20100004156A1 (en) | 2005-07-27 | 2010-01-07 | Shalesh Kaushal | Small Compounds That Correct Protein Misfolding and Uses Thereof |
| US20070212397A1 (en) * | 2005-09-15 | 2007-09-13 | Roth Daniel B | Pharmaceutical delivery device and method for providing ocular treatment |
| CA2631173A1 (en) | 2005-11-29 | 2007-06-07 | Smithkline Beecham Corporation | Treatment method |
| PL1971681T3 (pl) * | 2005-12-16 | 2018-01-31 | Depuy Synthes Products Inc | Kompozycje oraz sposoby do hamowania niepożądanej odpowiedzi immunologicznej w przypadku transplantacji z brakiem zgodności tkankowej |
| US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
| SG170789A1 (en) * | 2005-12-28 | 2011-05-30 | Ethicon Inc | Treatment of peripheral vascular disease using postpartum-derived cells |
| US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
| KR20140093764A (ko) | 2006-02-09 | 2014-07-28 | 산텐 세이야꾸 가부시키가이샤 | 안정한 제제와 그 제조 및 사용 방법 |
| US20070203190A1 (en) * | 2006-02-22 | 2007-08-30 | Ghanshyam Patil | Hydroxylamines and derivatives for the inhibition of complement activation |
| PL2001466T3 (pl) * | 2006-03-23 | 2016-06-30 | Santen Pharmaceutical Co Ltd | Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń |
| WO2007115259A2 (en) | 2006-03-31 | 2007-10-11 | Qlt Plug Delivery, Inc. | Nasolacrimal drainage system implants for drug therapy |
| WO2007133758A1 (en) * | 2006-05-15 | 2007-11-22 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
| DK2029746T3 (da) * | 2006-06-12 | 2012-10-08 | Exegenics Inc D B A Opko Health Inc | Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese |
| US8802128B2 (en) * | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US20080033008A1 (en) * | 2006-08-07 | 2008-02-07 | Ward Keith W | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof |
| CA2661607C (en) * | 2006-08-31 | 2012-06-26 | Bausch & Lomb Incorporated | Compositions and methods for treating or preventing glaucoma or progression thereof |
| US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
| US20110104159A1 (en) * | 2006-09-11 | 2011-05-05 | Rohrs Brian R | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
| EP2061444B1 (en) * | 2006-09-11 | 2011-04-20 | Bausch & Lomb Incorporated | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
| US20110105559A1 (en) * | 2006-09-11 | 2011-05-05 | Rohrs Brian R | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy |
| US20080145405A1 (en) * | 2006-12-15 | 2008-06-19 | Kunzler Jay F | Drug delivery devices |
| GB0713463D0 (en) | 2007-07-11 | 2007-08-22 | Btg Int Ltd | Modulators of hypoxia inducible factor-1 and related uses |
| CN101687786B (zh) | 2007-02-22 | 2013-05-22 | 奥特拉控股公司 | 羟胺化合物及其用法 |
| US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
| US20090042936A1 (en) * | 2007-08-10 | 2009-02-12 | Ward Keith W | Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation |
| US20090087443A1 (en) | 2007-09-27 | 2009-04-02 | Bartels Stephen P | Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery |
| CN102036688B (zh) * | 2007-10-05 | 2014-07-02 | 伊西康公司 | 使用人脐带组织来源的细胞进行肾脏组织的修复和再生 |
| US20100152646A1 (en) * | 2008-02-29 | 2010-06-17 | Reshma Girijavallabhan | Intravitreal injection device and method |
| US9023063B2 (en) | 2008-04-17 | 2015-05-05 | Apollo Endosurgery, Inc. | Implantable access port device having a safety cap |
| EP2300095B1 (en) | 2008-04-17 | 2015-03-11 | Apollo Endosurgery, Inc. | Implantable access port device and attachment system |
| US20090291073A1 (en) * | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
| US20100121441A1 (en) * | 2008-11-10 | 2010-05-13 | Nabil Jabbour | Surgical implant and method |
| JP5832293B2 (ja) | 2008-12-04 | 2015-12-16 | オプコ ファーマシューティカルズ、エルエルシー | 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法 |
| US20100143437A1 (en) * | 2008-12-09 | 2010-06-10 | Morris Edward J | Implantable analgesic |
| EP2379087B1 (en) * | 2008-12-19 | 2014-08-20 | DePuy Synthes Products, LLC | Umbilical cord tissue derived cells for treating neuropathic pain and spasticity |
| US10179900B2 (en) * | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
| JP6095893B2 (ja) * | 2008-12-19 | 2017-03-15 | デピュイ・シンセス・プロダクツ・インコーポレイテッド | 傷害後の神経組織の再生および修復 |
| WO2010071864A1 (en) | 2008-12-19 | 2010-06-24 | Ethicon, Incorporated | Treatment of lung and pulmonary diseases and disorders |
| EP2387394B1 (en) | 2009-01-14 | 2018-05-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| SG2014007389A (en) | 2009-01-29 | 2014-04-28 | Forsight Vision4 Inc | Posterior segment drug delivery |
| US9636255B2 (en) | 2009-02-13 | 2017-05-02 | Dose Medical Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| AU2010229651B2 (en) | 2009-03-26 | 2014-05-08 | Advanced Technologies And Regenerative Medicine, Llc | Human umbilical cord tissue cells as therapy for Alzheimer' s disease |
| US20110077270A1 (en) * | 2009-04-21 | 2011-03-31 | Pfeffer Bruce A | Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure |
| US8632511B2 (en) * | 2009-05-06 | 2014-01-21 | Alcon Research, Ltd. | Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2015073571A1 (en) * | 2013-11-15 | 2015-05-21 | Dose Medical Corporation | Ocular implants configured to store and release stable drug formulations |
| AU2010249683B2 (en) * | 2009-05-18 | 2015-06-25 | Glaukos Corporation | Drug eluting ocular implant |
| KR101429881B1 (ko) | 2009-06-03 | 2014-08-13 | 포사이트 비젼4, 인크. | 전안부 약물 전달 |
| IN2012DN00352A (me) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
| US8715158B2 (en) | 2009-08-26 | 2014-05-06 | Apollo Endosurgery, Inc. | Implantable bottom exit port |
| US8708979B2 (en) | 2009-08-26 | 2014-04-29 | Apollo Endosurgery, Inc. | Implantable coupling device |
| US8506532B2 (en) | 2009-08-26 | 2013-08-13 | Allergan, Inc. | System including access port and applicator tool |
| WO2011039648A1 (en) | 2009-09-30 | 2011-04-07 | Glaxo Wellcome Manufacturing Pte Ltd. | Methods of administration and treatment |
| WO2011069155A1 (en) * | 2009-12-04 | 2011-06-09 | Opko Ophthalmics, Llc | Compositions and methods for inhibition of vegf |
| US8177747B2 (en) * | 2009-12-22 | 2012-05-15 | Alcon Research, Ltd. | Method and apparatus for drug delivery |
| JP2013515741A (ja) * | 2009-12-23 | 2013-05-09 | サイヴィーダ ユーエス，インコーポレイテッド | 持続放出性送達デバイス |
| WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| US20110189174A1 (en) | 2010-02-01 | 2011-08-04 | Afshin Shafiee | Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization |
| US8882728B2 (en) | 2010-02-10 | 2014-11-11 | Apollo Endosurgery, Inc. | Implantable injection port |
| US8992415B2 (en) | 2010-04-30 | 2015-03-31 | Apollo Endosurgery, Inc. | Implantable device to protect tubing from puncture |
| US20110270025A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Remotely powered remotely adjustable gastric band system |
| US20110270021A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Electronically enhanced access port for a fluid filled implant |
| AU2011256259A1 (en) * | 2010-05-17 | 2012-11-08 | Novaer Holdings, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
| WO2011163560A1 (en) | 2010-06-25 | 2011-12-29 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Methods of treatment using sterculic acid |
| HRP20211909T1 (hr) | 2010-08-05 | 2022-03-18 | Forsight Vision4, Inc. | Uređaj za liječenja oka |
| CN105435338B (zh) | 2010-08-05 | 2019-03-26 | 弗赛特影像4股份有限公司 | 用于药物输送的注入器装置和方法 |
| WO2012019139A1 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
| US20120041258A1 (en) | 2010-08-16 | 2012-02-16 | Allergan, Inc. | Implantable access port system |
| US20120065460A1 (en) | 2010-09-14 | 2012-03-15 | Greg Nitka | Implantable access port system |
| CA2818612C (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
| US9233076B2 (en) | 2010-12-13 | 2016-01-12 | Purdue Pharma L.P. | Controlled release dosage forms |
| US8821373B2 (en) | 2011-05-10 | 2014-09-02 | Apollo Endosurgery, Inc. | Directionless (orientation independent) needle injection port |
| US20120316199A1 (en) | 2011-06-07 | 2012-12-13 | Ward Keith W | Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| CN106431988A (zh) | 2011-06-14 | 2017-02-22 | 比卡姆药品公司 | 视蛋白结合配体、组合物及使用方法 |
| US10398592B2 (en) | 2011-06-28 | 2019-09-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
| US8801597B2 (en) | 2011-08-25 | 2014-08-12 | Apollo Endosurgery, Inc. | Implantable access port with mesh attachment rivets |
| CN103889401B (zh) | 2011-08-29 | 2017-10-13 | Qlt公司 | 持续释放递送活性剂以治疗青光眼和高眼压 |
| US9974685B2 (en) | 2011-08-29 | 2018-05-22 | Mati Therapeutics | Drug delivery system and methods of treating open angle glaucoma and ocular hypertension |
| WO2013040426A2 (en) | 2011-09-14 | 2013-03-21 | Forsight Labs, Llc | Ocular insert apparatus and methods |
| DK2755600T3 (da) | 2011-09-16 | 2021-05-03 | Forsight Vision4 Inc | Fluidudvekslingsindretning |
| US9499464B2 (en) | 2011-10-19 | 2016-11-22 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
| US9199069B2 (en) | 2011-10-20 | 2015-12-01 | Apollo Endosurgery, Inc. | Implantable injection port |
| US8858421B2 (en) | 2011-11-15 | 2014-10-14 | Apollo Endosurgery, Inc. | Interior needle stick guard stems for tubes |
| US9089395B2 (en) | 2011-11-16 | 2015-07-28 | Appolo Endosurgery, Inc. | Pre-loaded septum for use with an access port |
| JP6126118B2 (ja) | 2011-11-30 | 2017-05-10 | ビカム ファーマスーティカルス，インコーポレイテッド | オプシン結合性リガンド、組成物、及び使用方法 |
| WO2013081642A1 (en) | 2011-12-01 | 2013-06-06 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
| JP6301263B2 (ja) | 2011-12-23 | 2018-03-28 | デピュイ・シンセス・プロダクツ・インコーポレイテッド | ヒト臍帯組織由来細胞の検出 |
| AU2013212271B2 (en) | 2012-01-24 | 2018-01-04 | Clarvista Medical, Inc. | Modular intraocular lens designs and methods |
| US9364316B1 (en) * | 2012-01-24 | 2016-06-14 | Clarvista Medical, Inc. | Modular intraocular lens designs, tools and methods |
| US10080648B2 (en) | 2012-01-24 | 2018-09-25 | Clarvista Medical, Inc. | Modular intraocular lens designs, tools and methods |
| US10028824B2 (en) | 2012-01-24 | 2018-07-24 | Clarvista Medical, Inc. | Modular intraocular lens designs, tools and methods |
| WO2013116061A1 (en) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
| KR101969594B1 (ko) * | 2012-05-11 | 2019-04-16 | 서강대학교산학협력단 | 안내 약물 전달 임플란트 |
| RU2652063C2 (ru) | 2012-10-26 | 2018-04-24 | Форсайт Вижн5, Инк. | Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу |
| EP2968613B1 (en) | 2013-03-11 | 2019-09-11 | University of Florida Research Foundation, Inc. | Delivery of card protein as therapy for occular inflammation |
| CA2905496A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| US9526654B2 (en) | 2013-03-28 | 2016-12-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
| JP6340673B2 (ja) | 2013-05-02 | 2018-06-13 | レティナ ファウンデーション オブ ザ サウスウエストＲｅｔｉｎａ Ｆｏｕｎｄａｔｉｏｎ Ｏｆ Ｔｈｅ Ｓｏｕｔｈｗｅｓｔ | 二層型眼用インプラント |
| ES2864274T3 (es) * | 2013-11-14 | 2021-10-13 | Eyed Pharma | Dispositivo ocular |
| AU2015219461B2 (en) | 2014-02-18 | 2019-10-31 | Alcon Inc. | Modular intraocular lens designs, tools and methods |
| WO2015184173A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US9580896B2 (en) | 2014-07-05 | 2017-02-28 | John David Hopkins | Apparatus and method for prolonged active agent in aqueous systems |
| KR102416726B1 (ko) | 2014-07-15 | 2022-07-05 | 포사이트 비젼4, 인크. | 안구 이식물 전달 디바이스 및 방법 |
| SG11201700943TA (en) | 2014-08-08 | 2017-03-30 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| CN114587774B (zh) | 2014-11-10 | 2024-07-19 | 弗赛特影像4股份有限公司 | 治疗眼睛的系统 |
| EP3250152B1 (en) | 2015-01-30 | 2025-03-12 | Alcon Inc. | Inserter for inserting a base and a lens of a modular intraocular lens into an eye |
| EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
| CA3002085A1 (en) | 2015-11-04 | 2017-05-11 | The Regents Of The University Of Colorado, A Body Corporate | Modular intraocular lens designs, tools and methods |
| WO2017087902A1 (en) | 2015-11-20 | 2017-05-26 | Forsight Vision4, Inc. | Porous structures for extended release drug delivery devices |
| WO2017176886A1 (en) | 2016-04-05 | 2017-10-12 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
| US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
| US11045309B2 (en) | 2016-05-05 | 2021-06-29 | The Regents Of The University Of Colorado | Intraocular lens designs for improved stability |
| SG11201811100RA (en) | 2016-07-05 | 2019-01-30 | Janssen Biotech Inc | Treatment of retinal vascular disease using progenitor cells |
| IL270575B2 (en) | 2017-06-13 | 2024-07-01 | Eyepoint Pharmaceuticals Inc | Biodegradable devices for drug delivery |
| US11382736B2 (en) | 2017-06-27 | 2022-07-12 | Alcon Inc. | Injector, intraocular lens system, and related methods |
| US11103460B2 (en) | 2017-08-07 | 2021-08-31 | Board Of Regents, The University Of Texas System | Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients |
| WO2019103906A1 (en) | 2017-11-21 | 2019-05-31 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
| AU2019275409B2 (en) | 2018-05-24 | 2024-08-15 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| US11690807B2 (en) | 2018-05-24 | 2023-07-04 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| EP3803866A4 (en) | 2018-05-24 | 2022-03-16 | Nureva Inc. | METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS |
| US11779739B2 (en) * | 2018-12-21 | 2023-10-10 | Perfect Ip, Llc | Drug delivery system and method |
| CA3132369A1 (en) | 2019-03-04 | 2020-09-10 | Duke University | Compositions and methods for the diagnosis and treatment of retinopathies |
| EP3861985B1 (en) | 2020-02-06 | 2023-06-14 | Ocular Therapeutix, Inc. | Compositions and methods for treating ocular diseases |
| US20240374599A1 (en) | 2020-02-26 | 2024-11-14 | Case Western Reserve University | Compositions and methods for treating misfolded protein ocular disorders |
| CN115461040B (zh) | 2020-03-25 | 2025-04-01 | 视尔普斯眼科公司 | 含有酪氨酸激酶抑制剂的眼用植入物 |
| CA3177005A1 (en) | 2020-04-27 | 2021-11-04 | Michael Goldstein | Methods of treating allergic conjunctivitis |
| AU2021347318A1 (en) | 2020-09-24 | 2023-03-23 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine |
| EP4216929A1 (en) | 2020-09-24 | 2023-08-02 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent |
| EP4329734A4 (en) | 2021-04-26 | 2025-04-02 | Celanese EVA Performance Polymers LLC | Implantable device for the delayed release of a macromolecular drug compound |
| US11357620B1 (en) | 2021-09-10 | 2022-06-14 | California LASIK & Eye, Inc. | Exchangeable optics and therapeutics |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
| AU2024251447A1 (en) | 2023-04-11 | 2025-08-21 | Ocular Therapeutix, Inc. | Ocular implant comprising axitinib polymorph iv |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2961629A (en) * | 1957-02-12 | 1960-11-22 | Lawrence J Kamm | Electrical connector for flexible cable |
| US3416530A (en) * | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
| US3896819A (en) * | 1969-04-01 | 1975-07-29 | Alejandro Zaffaroni | IUD having a replenishing drug reservoir |
| US3630200A (en) * | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3618604A (en) * | 1969-06-09 | 1971-11-09 | Alza Corp | Ocular insert |
| US3632739A (en) * | 1969-12-29 | 1972-01-04 | Sandoz Ag | Solid sustained release pharmaceutical preparation |
| US3980463A (en) * | 1970-11-16 | 1976-09-14 | Sumitomo Chemical Company, Limited | Process for producing granular composition for use in agriculture and horticulture |
| US3993071A (en) * | 1971-09-09 | 1976-11-23 | Alza Corporation | Bioerodible ocular device |
| US4036227A (en) * | 1973-04-25 | 1977-07-19 | Alza Corporation | Osmotic releasing device having a plurality of release rate patterns |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US3961628A (en) * | 1974-04-10 | 1976-06-08 | Alza Corporation | Ocular drug dispensing system |
| US4093708A (en) * | 1974-12-23 | 1978-06-06 | Alza Corporation | Osmotic releasing device having a plurality of release rate patterns |
| US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| US3977404A (en) * | 1975-09-08 | 1976-08-31 | Alza Corporation | Osmotic device having microporous reservoir |
| US4034758A (en) * | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
| US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4014334A (en) * | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
| US4247498A (en) * | 1976-08-30 | 1981-01-27 | Akzona Incorporated | Methods for making microporous products |
| US4111201A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
| US4111203A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
| US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4519909A (en) * | 1977-07-11 | 1985-05-28 | Akzona Incorporated | Microporous products |
| US4186184A (en) * | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
| JPS54119021A (en) * | 1978-03-06 | 1979-09-14 | Nippon Kayaku Co Ltd | Carcinostatic agent |
| US4290426A (en) * | 1978-05-04 | 1981-09-22 | Alza Corporation | Dispenser for dispensing beneficial agent |
| US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4730013A (en) * | 1981-10-08 | 1988-03-08 | Merck & Co., Inc. | Biosoluble ocular insert |
| DK90883A (da) * | 1982-03-18 | 1983-09-19 | Merck & Co Inc | Beholder til osmotisk afgivelse af et stof eller en stofblanding |
| US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4475916A (en) * | 1982-03-18 | 1984-10-09 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4432965A (en) * | 1982-07-09 | 1984-02-21 | Key Pharmaceuticals, Inc. | Quinidine sustained release dosage formulation |
| US4519801A (en) * | 1982-07-12 | 1985-05-28 | Alza Corporation | Osmotic device with wall comprising cellulose ether and permeability enhancer |
| US4522625A (en) * | 1982-09-29 | 1985-06-11 | Alza Corporation | Drug dispenser comprising wall formed of semipermeable member and enteric member |
| US4673405A (en) * | 1983-03-04 | 1987-06-16 | Alza Corporation | Osmotic system with instant drug availability |
| US4627850A (en) * | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4777049A (en) * | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
| EP0147780A3 (en) * | 1984-01-03 | 1987-03-11 | Merck & Co. Inc. | Drug delivery device |
| IT1206166B (it) * | 1984-07-26 | 1989-04-14 | Sigma Tau Ind Farmaceuti | Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione |
| US4692336A (en) * | 1984-03-19 | 1987-09-08 | Alza Corporation | Self controlled release device for administering beneficial agent to recipient |
| US4716031A (en) * | 1984-03-21 | 1987-12-29 | Alza Corporation | Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug |
| US4615698A (en) * | 1984-03-23 | 1986-10-07 | Alza Corporation | Total agent osmotic delivery system |
| US4657543A (en) * | 1984-07-23 | 1987-04-14 | Massachusetts Institute Of Technology | Ultrasonically modulated polymeric devices for delivering compositions |
| US4927687A (en) * | 1984-10-01 | 1990-05-22 | Biotek, Inc. | Sustained release transdermal drug delivery composition |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4913906B1 (en) * | 1985-02-28 | 2000-06-06 | Yissum Res Dev Co | Controlled release dosage form of valproic acid |
| US4693886A (en) * | 1985-04-22 | 1987-09-15 | Alza Corporation | Osmotic device with inert core |
| US4624847A (en) * | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
| US4609374A (en) * | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
| US4720384A (en) * | 1985-05-03 | 1988-01-19 | E. I. Du Pont De Nemours And Company | Manufacture of hollow fine tubular drug delivery systems |
| US4898733A (en) * | 1985-11-04 | 1990-02-06 | International Minerals & Chemical Corp. | Layered, compression molded device for the sustained release of a beneficial agent |
| US4717567A (en) * | 1985-11-25 | 1988-01-05 | Eastman Kodak Company | Rumen-stable pellets |
| IT1188212B (it) * | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
| US5141752A (en) * | 1986-05-09 | 1992-08-25 | Alza Corporation | Delayed drug delivery device |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4786500A (en) * | 1986-06-26 | 1988-11-22 | Alza Corporation | Programmable agent delivery system |
| JPH0794384B2 (ja) * | 1986-09-01 | 1995-10-11 | 帝国製薬株式会社 | 徐放性口腔内用製剤 |
| US4806382A (en) * | 1987-04-10 | 1989-02-21 | University Of Florida | Ocular implants and methods for their manufacture |
| US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
| US4891223A (en) * | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
| US4994273A (en) * | 1987-11-02 | 1991-02-19 | Merck & Co., Inc. | Solubility modulated drug delivery device |
| IT1223150B (it) * | 1987-11-18 | 1990-09-12 | Ubaldo Conte | Compressa per uso oftalmico e rilascio controllato della sostanza attiva |
| US4877618A (en) * | 1988-03-18 | 1989-10-31 | Reed Jr Fred D | Transdermal drug delivery device |
| US4865846A (en) * | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
| US4882150A (en) * | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
| US5098443A (en) * | 1989-03-23 | 1992-03-24 | University Of Miami | Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents |
| US5028435A (en) * | 1989-05-22 | 1991-07-02 | Advanced Polymer Systems, Inc. | System and method for transdermal drug delivery |
| JPH05503934A (ja) * | 1990-01-30 | 1993-06-24 | アクゾ・エヌ・ヴエー | 壁により完全に包囲され、１種以上の活性物質で全部又は一部を充填した中空空間から成る、活性物質の調節送達のための物品 |
| US5091185A (en) * | 1990-06-20 | 1992-02-25 | Monsanto Company | Coated veterinary implants |
| US5525601A (en) * | 1990-09-07 | 1996-06-11 | Universidad De Alicante | Composition for treating ocular pain |
| IS3778A7 (is) * | 1990-10-31 | 1992-05-02 | Amgen Inc. | Aðferð til að gefa dýrum vaxtarhormón, þar sem gefnu magni er stýrt |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5435998A (en) * | 1994-08-03 | 1995-07-25 | Abelson; Mark B. | Treatment of low-tension glaucoma by topical administration of calcium channel blocking agents |
-
1997
- 1997-08-28 US US08/919,221 patent/US5902598A/en not_active Expired - Lifetime
-
1998
- 1998-08-27 TW TW087114137A patent/TWI222884B/zh not_active IP Right Cessation
- 1998-08-28 UA UA2000031729A patent/UA71898C2/uk unknown
- 1998-08-28 CZ CZ20000604A patent/CZ302339B6/cs not_active IP Right Cessation
- 1998-08-28 CA CA002301685A patent/CA2301685C/en not_active Expired - Fee Related
- 1998-08-28 PL PL98344039A patent/PL344039A1/xx unknown
- 1998-08-28 KR KR1020007001996A patent/KR20010023358A/ko not_active Ceased
- 1998-08-28 ME MEP-2008-200A patent/ME00122B/me unknown
- 1998-08-28 JP JP2000508347A patent/JP4530531B2/ja not_active Expired - Fee Related
- 1998-08-28 NZ NZ502836A patent/NZ502836A/xx unknown
- 1998-08-28 CN CNB988103753A patent/CN100453074C/zh not_active Expired - Fee Related
- 1998-08-28 BR BR9811381-0A patent/BR9811381A/pt not_active Application Discontinuation
- 1998-08-28 IL IL13456898A patent/IL134568A/xx not_active IP Right Cessation
- 1998-08-28 SG SG200203462A patent/SG121718A1/en unknown
- 1998-08-28 AR ARP980104323A patent/AR017026A1/es not_active Application Discontinuation
- 1998-08-28 EA EA200000267A patent/EA002162B1/ru not_active IP Right Cessation
- 1998-08-28 TR TR2000/01029T patent/TR200001029T2/xx unknown
- 1998-08-28 WO PCT/US1998/017342 patent/WO1999011244A1/en not_active Ceased
- 1998-08-28 AU AU90291/98A patent/AU741846B2/en not_active Ceased
- 1998-08-28 AT AT98942180T patent/ATE548029T1/de active
- 1998-08-28 RS YU11100A patent/RS52096B/sr unknown
- 1998-08-28 EP EP98942180A patent/EP1009388B1/en not_active Expired - Lifetime
- 1998-08-28 ME MEP-200/08A patent/MEP20008A/xx unknown
- 1998-08-28 CN CNA2007101933400A patent/CN101327197A/zh active Pending
- 1998-08-28 HU HU0002797A patent/HUP0002797A3/hu unknown
-
2000
- 2000-02-14 NO NO20000735A patent/NO327752B1/no not_active IP Right Cessation
-
2002
- 2002-03-11 NZ NZ517736A patent/NZ517736A/en not_active IP Right Cessation
-
2010
- 2010-03-01 JP JP2010044187A patent/JP2010168388A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00122B (me) | Sistemi koji obezbjeđuju podržano oslobađanje lijeka | |
| JP2003517425A5 (me) | ||
| EP0521074B1 (en) | Dosage form for delivering drug to the intestine | |
| US3699963A (en) | Therapeutic adhesive patch | |
| US5455043A (en) | Device for controlled release of vaporous medications through nasal route | |
| US5071704A (en) | Device for controlled release of vapors and scents | |
| KR920703026A (ko) | 부하제를 포함한 장기간 전달 장치 | |
| US4721613A (en) | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use | |
| US4863744A (en) | Intestine drug delivery | |
| US5260068A (en) | Multiparticulate pulsatile drug delivery system | |
| CN101242815B (zh) | 用于从聚合物中释放一氧化氮的包含微胶囊化的质子给体的装置、系统、和方法 | |
| AU1824299A (en) | Polymeric microporous film coated subcutaneous implants | |
| IL93956A (en) | Transdermal therapeutic system exhibiting an increased active substance flow and process for the production thereof | |
| CN115475048B (zh) | 滥用和误用制止透皮系统 | |
| CA2104699A1 (en) | Sustained release drug delivery devices | |
| SE9002339L (sv) | Terapeutisk komposition och foerfarande foer dess framstaellning | |
| ATE238774T1 (de) | Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt | |
| DE69619668D1 (de) | Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon | |
| US4851231A (en) | System for delivering drug in selected environment of use | |
| CN1708291A (zh) | 具有改良的长期附着舒适性的透皮治疗体系 | |
| US4948593A (en) | Osmotic dosage form comprising an estrogen and a progestogen | |
| US5167962A (en) | Filament system for delivering a medicament and method | |
| KR19990071871A (ko) | 피부 도포용 표면 안정화 약제 | |
| HK40085268A (en) | Abuse and misuse deterrent transdermal systems | |
| HK40085268B (zh) | 滥用和误用制止透皮系统 |